CFO appointment
Quince Therapeutics, Inc. appoints John Militello as CFO
Quince Therapeutics, Inc. reported in a Form 8-K filed July 31, 2026 that John Militello was appointed Chief Financial Officer.
In the filing's words
John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer and will serve as the Company’s Principal Financial Officer and Principal Accounting Officer upon his appointment.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Quince Therapeutics, Inc. (QNCX) |
|---|---|
| Event | Appointment |
| Incoming | John Militello |
| Title in the filing | Chief Financial Officer |
| Effective | not stated in the source |
| 8-K filed | July 31, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Head of Finance, Orphai Therapeutics, LLC |
| SEC CIK | 0001662774 |
Quince Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed July 31, 2026. The filing's own words are quoted above.
Same industry, July 2026
4Other moves filed that month at companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
3 months ago· 2026-07-27TransitionDTIL
Precision BioSciences, Inc. CFO transition: Naresh Tanna to succeed Alex Kelly
3 months ago· 2026-07-23TransitionIMA
ImageneBio, Inc. CFO transition: Yanina Grant-Huerta to succeed Kristin Yarema, Ph.D.
3 months ago· 2026-07-20AppointmentARMP
Armata Pharmaceuticals, Inc. appoints David House as CFO
3 months ago· 2026-07-20AppointmentKLRS
Kalaris Therapeutics, Inc. appoints Liisa Bayko as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Documented unknowns
- effective: The filing gives "the Effective Time", which is not a calendar date.
Something wrong about John Militello? Send a correction with the primary source.